Therapeutic Modulation of Plasmacytoid Dendritic Cells in Experimental Arthritis

0
0 / 5 (0 votos)

Arthritis & Rheumatology

Published online: 27 October 2017

DOI: 10.1002/art.40225

Ramzi Nehmar PhD, Ghada Alsaleh MD, PhD, Benjamin Voisin PhD, Vincent Flacher PhD, Alexandre Mariotte MS, Victoria Saferding MS, Antonia Puchner MS, Birgit Niederreiter MS, Thierry Vandamme PhD, Gernot Schabbauer PhD, Philippe Kastner PhD, Susan Chan PhD, Peggy Kirstetter PhD, Martin Holcmann PhD, Christopher Mueller PhD, Jean Sibilia MD, PhD, Seiamak Bahram MD, PhD, Stephan Blüml MD, PhD, Philippe Georgel PhD

Objectives: The role of plasmacytoid dendritic cells (PDCs) and type I interferons (IFNs) in rheumatoid arthritis (RA) remains a subject of controversy. This study was undertaken to explore the contribution of PDCs and type I IFNs to RA pathogenesis using various animal models of PDC depletion and to monitor the effect of localized PDC recruitment and activation on joint inflammation and bone damage.